BiotechTube

Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine

Phase 1/2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma

Trial Timeline

Sep 1, 2008 → Dec 1, 2012

NCT ID
NCT00807196

About Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine

Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + Fludarabine is a phase 1/2 stage product being developed by Bayer for Non-Hodgkins Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00807196. Target conditions include Non-Hodgkins Lymphoma.

Hype Score Breakdown

Clinical
9
Activity
4
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00807196Phase 1/2UNKNOWN

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
32
JBH492NovartisPhase 1
21
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2CRochePhase 1/2
36
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
35
hLL2 (epratuzumab)Gilead SciencesPhase 1
21
Velcade + TemsirolimusPfizerPhase 2
35
alemtuzumabSanofiPhase 1/2
24
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
36
Rituximab + Fludarabine + CAMPTH-1HBayerPhase 2
32
Rituximab + CHOP + CVP + Ibritumomab TiuxetanBiogenPhase 2
32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
32
UblituximabTG TherapeuticsPhase 1/2
29
Ublituximab + LenalidomideTG TherapeuticsPhase 1
18
XmAb13676XencorPhase 1
23